Published online Sep 12, 2026. doi: 10.5318/wjo.119850
Revised: February 28, 2026
Accepted: April 29, 2026
Published online: September 12, 2026
Processing time: 215 Days and 4.7 Hours
Magnetic resonance imaging (MRI) is the reference modality for evaluating disea
Core Tip: Magnetic resonance imaging plays a central role in evaluating optic nerve and optic chiasmal disorders, yet diagnostic uncertainty often arises from overlapping clinical presentations. This mini-review introduces a practical, pattern-based magnetic resonance imaging framework that emphasizes protocol optimization, key enhancement and diffusion features, and common imaging pitfalls specific to the anterior visual pathway. By highlighting distinguishing imaging phenotypes across inflammatory, ischemic, compressive, neoplastic, and vascular etiologies, this review provides ra
- Citation: Tlaiss Y, Hmayed J, Mneimneh M, Sarraf G, Gharios R, Zalzali I, Tarchichi A. Magnetic resonance imaging in the diagnosis of optic nerve and chiasmal pathologies. World J Ophthalmol 2026; 10(1): 119850
- URL: https://www.wjgnet.com/2218-6239/full/v10/i1/119850.htm
- DOI: https://dx.doi.org/10.5318/wjo.119850
Vision-threatening disorders of the optic nerve and optic chiasm arise from diverse mechanisms – most commonly inflammatory demyelination, ischemia, infiltration, and extrinsic compression – and often converge on a limited set of clinical presentations, including acute or progressive visual loss, dyschromatopsia, relative afferent pupillary defect, and sometimes subtle visual field defects. Because early management can be time-sensitive (e.g., distinguishing inflammatory demyelination from arteritic ischemia or compressive lesions), imaging is integral to contemporary neuro-ophthalmic decision-making[1]. Clinical examination, perimetry, and optical coherence tomography (OCT) remain essential, but they may not reliably localize pathology to the optic nerve vs chiasm, define lesion extent, or separate etiologic categories – particularly when disc findings are absent, atypical, or delayed. A magnetic resonance imaging (MRI)-oriented overview of the anterior visual pathway and common disease locations is summarized in Figure 1.
MRI is the reference cross-sectional modality for evaluating the anterior visual pathway because it offers superior soft-tissue contrast, multiplanar capability, and comprehensive assessment of the orbits, optic canals, intracranial optic pathways, and parasellar region within a single examination. Dedicated orbital protocols – typically combining thin-section fat-suppressed T2-weighted imaging, pre-contrast and post-contrast fat-suppressed T1-weighted sequences, and brain MRI to assess associated intracranial disease – enable detection of optic nerve edema, enhancement patterns, sheath-based disease, and tract/chiasmal involvement. Beyond conventional sequences, diffusion-weighted imaging (DWI) can support ischemic or hypercellular pathology, while advanced techniques such as diffusion tensor imaging (DTI) and tractography have shown promise for microstructural assessment of optic pathways and for research-grade biomarkers[1].
MRI is also central to risk stratification and systemic workup. In typical optic neuritis, concomitant brain MRI abnor
This review provides an ophthalmology-forward, pattern-based approach to MRI of optic nerve and chiasmal disease. We first summarize practical MRI techniques and sequences relevant to the anterior visual pathway, then synthesize characteristic imaging findings across major etiologic categories: (1) Inflammatory/demyelinating disorders; (2) Compressive and neoplastic lesions; and (3) Ischemic/vascular pathologies. Our goal is to help clinicians recognize high-yield MRI patterns, understand their prognostic and systemic implications, and integrate imaging findings into timely, patient-centered management.
MRI is a noninvasive, non-radiating imaging technique especially used for the visualization of the brain, spinal cord, and soft tissues. MRI generates images based on proton behavior within a magnetic field, producing high-contrast soft-tissue detail essential for optic pathway evaluation. A practical orbit-first MRI protocol and common add-on sequences based on the clinical question are outlined in Figure 2.
T1-weighted sequences: T1-weighted MRI sequence is also known as the anatomic sequence, since it serves as a reference point to which pathological findings are compared. T1 images depend on the rate at which resonating protons realign with the main magnetic field after receiving the radiofrequency pulse; this is known as the T1 relaxation time[5]. Tissues that realign slowly, such as urine, water, or cerebrospinal fluid, appear with low signal intensity (dark) whereas tissues that realign rapidly, such as fat, appear with high signal intensity (white). Muscles have an intermediate signal intensity, appearing grey. In the brain the grey matter has an intermediate signal whereas the white matter is more hyperintense and appears brighter[6]. T1-weighted sequences are also used to assess enhancing lesions in postcontrast studies (most commonly intravenous gadolinium); pathological findings such as areas of infection, tumors, and inflammation show accumulation of contrast material due to vascular leakage. In addition, fat suppression may be used in postcontrast T1 sequences for better visualization[6].
Fat suppressed sequences: Fat suppression MRI sequences are sequences that suppress the bright hyperintense fat signal, making it appear dark. This allows clarity and better detection of pathologies such as inflammation, tumors, or injury. This technique is also useful for appreciating tissues enhanced by contrast material. Demonstration of signal suppression on fat-suppressed sequences can confirm the presence of fat within a lesion[6]. Several fat-suppression techniques may be selected based on the clinical indication and anatomic region of interest; these include frequency-selective fat saturation, short tau inversion recovery, chemical shift selective techniques (DIXON), and others[7]. In orbital imaging, fat su
T2-weighted sequences: The T2-weighted sequence is also known as the pathological sequence. While the T1 sequence works by the relaxation of protons back along the main magnetic vector (T1 relaxation time), T2 depends on how rapidly these excited protons lose phase coherence (proton spin decay) after the radiofrequency pulse; this is known as the T2 transverse relaxation time[5]. Water molecule protons have fewer interactions with their microenvironment compared with the less mobile protons of other tissues; resulting in a longer spin decay. Consequently, tissues having a prolonged T2 imply that they retain the signal longer, making water rich tissue appear with high signal intensity. This makes this sequence capable of highlighting differences in tissue water content[5]. Hence, on T2, fluid appears with high signal, fat with intermediate to high signal and muscle with intermediate signal. In the brain the grey matter has an intermediate signal whereas the white matter is more hypointense and appears darker[6].
Fluid attenuated sequences: Fluid attenuated inversion recovery (FLAIR) is a sequence used to suppress the high intensity signal from free fluid and specifically cerebrospinal fluid. This modification allows clear visualization of areas where edema, inflammation, or demyelination would otherwise be obscured by the cerebrospinal fluid high signal. FLAIR imaging is particularly useful in neuroimaging because suppression of cerebrospinal fluid signal improves visualization of demyelinating plaques[6].
DWI: DWI MRI is a specialized technique that captures the random Brownian motion of water molecules within tissues, reflecting their microanatomy. The diffusion of water is influenced by cellular structures such as membranes and extrace
DTI: DTI builds upon the principles of DWI by measuring the directionality of water movement. In nerve fibers, water does not diffuse equally in all directions; instead, it preferentially moves along the length of axons due to the presence of barriers like the cell membranes and myelin. Fractional anisotropy (FA) is then calculated, which reflects how strongly water movement is focused in one direction. A higher FA value usually implies that the nerve fibers are healthy and well-organized. The mean diffusivity represents the average amount of water movement, independent of direction[5].
One of the key advantages of DTI is its ability to perform tractography, which is a method that reconstructs the pathways of white matter tracts. Tractography provides a three-dimensional representation and clear visualization of complex structures such as the optic nerves, optic chiasm, and optic radiations[5]. For example, in their review, Hoch et al[1] discuss how DTI and tractography have been used to study several optic nerve disorders. In glaucoma, DTI has revealed reduced FA and increased mean diffusivity in the optic nerves, optic tracts, and optic radiations, even before significant structural damage is visible on traditional MRI. Similarly, in optic neuritis, an inflammatory condition often associated with MS, DTI has shown decreased FA in the affected optic nerve, indicating demyelination and axonal injury. These findings suggest that DTI can detect early microstructural changes, potentially allowing for earlier diagnosis and monitoring of disease progression[1].
Magnetic resonance arteriography/venography: Magnetic resonance angiography (MRA) is an imaging modality used to visualize arterial blood vessels with high spatial resolution. MRA primarily relies on differences in the magnetic properties of flowing blood compared to stationary tissues. Time of flight MRA is a technique which uses gradient echo sequences sensitive to inflowing blood spins that have not yet been saturated by repeated radiofrequency pulses. This makes arterial blood flowing towards the imaged section appear with high signal while static tissue appears suppressed. Another technique is phase contrast MRA, which encodes the velocity of moving protons, allowing quantification of blood flow and the visualization of the vessel lumen. Gadolinium enhanced MRA further improves vessel visibility by shortening T1 relaxation time of blood, producing high signal intensity in arteries. MRA is particularly useful for detecting arterial stenosis, aneurysms, dissections, and vascular malformations. However, limitations include sensitivity to turbulent or slow flow, which may cause signal loss or artifacts[5].
Magnetic resonance venography (MRV), on the other hand, is more challenging due to the slower and more variable blood flow of the venous system. Time of flight MRV can be performed with adjustments such as longer echo times for venous flow detection. Gadolinium-enhanced MRV similarly produces high intensity venous signals by reducing T1 relaxation time. Phase contrast MRV can also assess for venous occlusions or thrombosis[5]. As a result, MRA and MRV are developed vascular imaging modalities that avoid risks of conventional catheter angiography while producing a detailed assessment of both arterial and venous systems.
High-resolution orbital MRI: High-resolution orbital MRI at ultrahigh field strength has revolutionized imaging of the complex anatomy of the eye and orbit. Glarin et al[10] highlighted that increasing the magnetic field strength to 7 Tesla provided a significantly higher signal to noise ratio compared to the standard clinical scanners of 1.5 Tesla and 3 Tesla, allowing the imaging with exceptional spatial resolution. Operating with thinner slices, often less than 1 millimeter thick, and imaging in the coronal plane leads to enhanced visualization of the optic nerve sheath, extraocular muscles, lacrimal gland, and small vessels within the orbit. Such technical enhancements minimize artifacts, and improve contrast differentiation between soft tissues, which is crucial for the detection of subtle pathological changes. Furthermore, high resolution MRI improves advanced imaging techniques, including DTI and susceptibility weighted imaging, providing further microstructural and vascular information. Note that susceptibility weighted imaging is a sequence sensitive to compounds that alter the local magnetic field such as blood products or calcium. Glarin et al[10] also note that despite the benefits, challenges including increased susceptibility artifacts and specific absorption rate concerns persist. Hence optimized protocols are required to ensure patient safety and image quality. In conclusion, the 7 Tesla orbital MRI is promising in developing higher diagnostic accuracy and better understanding of orbital diseases[10].
MRI contrast: The most commonly used MRI contrast agents are gadolinium-based contrast agents (GBCAs), which contain the paramagnetic ion gadolinium (Gd³+) bound within a chelating molecule to reduce toxicity. Gadolinium works by shortening the T1 and T2 relaxation times of water protons (mainly T1 shortening), which results in a higher signal intensity[5]. This enhancement allows the detection and characterization of lesions, especially in areas where the blood brain barrier is disrupted or where pathologic vascularity is present, such as tumors, inflammation, infections, or vascular malformations. The clinical indications for gadolinium use are broad but should be led by whether administration of contrast material will provide critical diagnostic information influencing patient management. For example, in oncology, GBCAs allow the differentiation of tumor tissue from edema, assessment of tumor margins, detection of metastases, and treatment response monitoring. However, in neuroimaging GBCAs help in identification of active demyelinating lesions in MS. Additionally, contrast agents enhance the visualization of blood vessels and vascular abnormalities in MRA and venography[5].
Despite its advantages, gadolinium contrast use involves important safety considerations and potential pitfalls. Patients with renal impairment are at risk of developing nephrogenic systemic fibrosis usually 2-10 weeks post contrast administration, prompting screening renal function prior to contrast administration[11]. Additionally, allergic reactions, though uncommon, can range from mild hypersensitivity to severe anaphylaxis. Overall, knowledge of gadolinium’s pharmacokinetics and safety profile are essential to maximize diagnostic benefits while minimizing risks associated with contrast enhanced MRI[11].
MRI is the primary imaging modality for evaluating inflammatory and demyelinating disorders of the optic nerve and chiasm. In patients presenting with optic neuropathy, MRI helps distinguish typical MS-associated optic neuritis from antibody-mediated optic neuritis, including NMOSD and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), as well as from infectious and granulomatous etiologies. Because lesion distribution and enhancement patterns correlate with prognosis and influence systemic workup, familiarity with these imaging phenotypes is essential for ophthalmologists and neuro-ophthalmologists.
Typical MS-associated optic neuritis most often demonstrates short-segment involvement (classically < 50% of the optic nerve length) with T2 hyperintensity and gadolinium enhancement, frequently centered in the posterior intraorbital and/or canalicular segments. Chiasmal involvement is uncommon. Brain MRI performed concurrently may demonstrate characteristic demyelinating lesions and can support an MS-related etiology. In addition, baseline MRI findings contri
NMOSD optic neuritis is more likely to show longitudinally extensive involvement (often > 50% of the optic nerve length), bilateral disease, and posterior extension with more frequent chiasmal involvement compared with typical MS-associated optic neuritis. Enhancement may be intense and continuous. When these features are present, clinicians should pursue targeted serologic testing for aquaporin-4 antibodies and obtain MRI of the brain and spinal cord, as imaging contributes to diagnostic confirmation and may change acute and long-term treatment strategies. NMOSD-associated optic neuritis is often associated with poorer visual outcomes than typical MS-associated optic neuritis, emphasizing the importance of early recognition and appropriate immunotherapy[13].
MOGAD optic neuritis commonly involves the anterior optic nerve and may demonstrate perineural or optic nerve sheath enhancement, often correlating clinically with optic disc swelling. Bilateral involvement is common, and visual recovery is frequently favorable compared with NMOSD, though relapses may occur. While MRI findings are not pathognomonic, the combination of imaging patterns, clinical features, and MOG antibody testing supports diagnosis and informs prognosis and follow-up[14]. Key MRI phenotype differences across MS-associated, NMOSD-associated, and MOGAD-associated optic neuritis are summarized in Figure 3.
Infectious optic neuritis – such as syphilitic, tuberculous, or viral etiologies – can mimic demyelinating optic neuritis and should be considered in atypical presentations, severe or bilateral disease, prominent meningeal features, or steroid-refractory cases. MRI may show variable optic nerve enhancement, sometimes with associated meningeal enhancement or other intracranial inflammatory findings. Accurate diagnosis relies on correlation with systemic symptoms, exposure history, laboratory testing, and, when appropriate, cerebrospinal fluid evaluation[15].
Granulomatous and systemic inflammatory diseases (including sarcoidosis and vasculitis) may involve the optic nerve, sheath, chiasm, or adjacent meninges. MRI often demonstrates patchy or nodular enhancement, and disease may extend to the hypothalamus or pituitary region depending on the underlying etiology. When these patterns are suspected, imaging should prompt systemic evaluation tailored to the clinical context, as diagnosis frequently depends on multisystem findings[16].
MRI findings provide actionable prognostic and management information. Short-segment involvement without chiasmal extension favors typical MS-associated optic neuritis and is often associated with better visual recovery. In contrast, extensive longitudinal disease, bilateral involvement, and chiasmal extension raise concern for NMOSD or other aggressive inflammatory etiologies and are linked to worse outcomes and higher relapse risk, warranting urgent targeted testing and multidisciplinary management. Integrating MRI patterns with clinical examination and disease course helps guide therapy, counseling, and follow-up intensity[17].
Common compressive sites along the optic nerve-chiasm axis and their typical visual field correlates are illustrated in Figure 4.
Children with neurofibromatosis type 1 (NF1) are predisposed to glial neoplasms involving the visual pathway and have a 15%-20% risk of developing an optic pathway glioma[18]. NF1-associated optic pathway gliomas most commonly arise within the optic nerve and may extend to the optic chiasm and tracts, leading to progressive vision decline, strabismus, and proptosis. However, surveillance is recommended and effective treatments (chemotherapy, targeted therapy, and selected surgical approaches) are available[18].
In a symptomatic child, contrast-enhanced MRI of the brain and orbits is the imaging modality of choice to assess localization, complications, and tumor extension along the visual pathway[19,20]. Importantly, MRI-defined tumor growth does not reliably predict visual outcome in NF1-optic pathway glioma, and conversely vision can decline despite stable-appearing MRI[21]. Therefore, structured surveillance with regular ophthalmologic monitoring is essential, and serial MRI is recommended when progression is suspected, particularly when treatment decisions and planning are urgent[21].
On MRI, optic pathway gliomas typically show tubular enlargement of the optic nerve and/or chiasm with variable T2 hyperintensity and enhancement. Lesions may show mixed cystic-solid components or expansion along the nerve/chiasm depending on extent[22]. Accordingly, treatment decisions are guided by documented functional decline and clinically meaningful progression, while MRI is used to map the full extent of involvement, characterize mass effect, and support multidisciplinary planning rather than relying on tumor size alone[18,21,22].
ONSM is a rare benign tumor arising from the meninges of the optic nerve, representing approximately 1%-2% of meningiomas. It is classically a compressive extra-axial neoplasm in adults, with a female predominance, and presents with painless, slowly progressive monocular visual loss and visual field defects[23].
ONSM is distinguished from optic nerve glioma and other lesions on MRI by a sheath-based, avidly enhancing lesion encasing the optic nerve, best seen on post-contrast fat-suppressed T1 sequences. It typically shows a “tram-track” sign. MRI defines the longitudinal extent along the sheath, degree of optic nerve compression, and relationship to the globe and orbital apex – details critical for management planning and prognosis, particularly when modern radiation strategies are considered[24].
While surgery remains an option in selected cases, fractionated stereotactic radiotherapy is widely considered a vision-preserving strategy. Fractionated stereotactic radiotherapy demonstrates high rates of long-term improvement or stabilization in visual acuity and visual field metrics with low complication rates in most patients[25]. Proton therapy similarly reports mostly stable visual outcomes while highlighting rare but serious radiation-induced optic neuropathy risk and the need for careful MRI-based planning[26].
When MRI is suggestive but not definitive, (68)Ga-DOTATOC positron emission tomography/computed tomography (CT) can provide highly sensitive supportive evidence for ONSM, which is important because diagnostic confidence directly affects the decision to observe vs proceed to radiotherapy rather than biopsy or surgery[23].
Several space-occupying lesions in and around the orbit can present with similar symptoms, but differentiation is essential because etiology and extent guide management. These include, among other causes, orbital lymphoma and metastatic disease. Such lesions can infiltrate any orbital structure, involve the optic nerve, and extend intracranially to affect the optic chiasm and sellar compartment. They usually manifest as subacute progressive visual loss and visual field defects and, with orbital apex involvement, may cause proptosis, diplopia, ophthalmoplegia, or pain[27].
Most orbital metastases occur in the anterior orbit and may appear as circumscribed enhancing lesions, with imaging characteristics varying by primary tumor. Common primaries include breast, lung, prostate, melanoma, carcinoid, gastrointestinal malignancies, renal cell carcinoma, neuroblastoma, and rhabdomyosarcoma[28].
Primary central nervous system lymphoma represents a minority of primary brain tumors and often presents with nonspecific neurologic symptoms; although histology remains the gold standard, imaging is essential for diagnosis and differential. Primary central nervous system lymphoma typically appears as a well-defined lesion with characteristic signal and homogeneous enhancement patterns[29]. Malignant lymphoma of the orbit commonly arises from ocular adnexal lymphoid tissue and is frequently B-cell lymphoma. For such highly cellular tumors, DWI is a crucial discriminator because it often demonstrates marked diffusion restriction with low ADC and high DWI signal, improving diagnostic confidence compared with conventional sequences[30]. These findings are supported by a case series and systematic review showing lower ADC values in lymphoma and malignant orbital lesions compared with idiopathic orbital inflammation, with minimal overlap[31]. MRI should be interpreted in close correlation with the ophthalmic exam, but it often provides decisive lesion characterization as homogeneous, lobulated masses that mold around structures rather than deforming them[27,31].
MRI and DWI can directly shape the management pathway by increasing confidence for lymphoma vs inflammatory pseudotumor vs other tumors/metastases, accelerating appropriate systemic/oncology workup and helping avoid inappropriate primary surgery for lesions best treated medically. When biopsy is necessary, MRI helps determine the most productive target and supports safe trajectory planning by mapping lesion extent[32].
Pituitary adenomas arise from the adenohypophysis within the sella turcica and are classified as microadenomas (< 10 mm) and macroadenomas (≥ 10 mm). They present with local mass effect – most notably suprasellar extension with optic chiasm compression and/or cavernous sinus invasion – or with endocrine dysfunction[33]. Symptoms such as headache, cranial nerve palsies (III, IV, VI), and visual field defects (classically bitemporal hemianopia) depend on the degree of chiasmal compression. A large Johns Hopkins study correlated visual field abnormalities with MRI-quantified optic pathway compression, supporting the concept that MRI-defined chiasmal involvement can frame expectations regarding postoperative visual recovery[34].
MRI remains the key modality for diagnosis and preoperative mapping. Many sellar differentials, including hypophysitis and Rathke cleft cyst, can mimic pituitary adenoma and are often distinguishable on MRI. Macroadenomas may show sellar enlargement with variable T1/T2 signal and enhancement patterns, while microadenomas typically appear as focal hypoenhancing lesions best detected on dynamic contrast-enhanced imaging. MRI also characterizes suprasellar growth, cavernous sinus and carotid artery involvement, and parasellar extension, guiding urgency, approach selection, and surgical planning[35].
Anterior skull base tumors, including craniopharyngioma and tuberculum sellae meningioma, commonly present with optic chiasm compression leading to visual field loss and may be associated with endocrine dysfunction, cognitive symptoms, and headaches. MRI is the main modality to differentiate these lesions and plan treatment, and it guides resection strategy in a region dense with critical neurovascular structures.
Craniopharyngiomas are epithelial, nonmalignant tumors centered in the sellar-suprasellar region that can result in neurologic, endocrinologic, and psychiatric morbidity if untreated. They typically appear as heterogeneous cystic-solid masses with mixed signal intensity and enhancing solid components. MRI defines suprasellar extension, third-ventricle involvement, and hypothalamic relationship, which influence symptoms and surgical strategy. A radiologic grading approach to hypothalamic involvement has been used to support surgical decision-making and long-term outcome prediction[36]. Surgical route selection is also MRI-informed; comparative data suggest endoscopic endonasal approaches may yield better visual outcomes in selected cases but with higher cerebrospinal fluid leak risk[37]. In selected molecular subtypes, MRI also documents response to targeted therapy and tumor shrinkage during follow-up[38].
Tuberculum sellae meningioma represents a minority of intracranial meningiomas and frequently presents with visual loss. Adequate surgical planning is MRI-based because approach selection influences postoperative visual improvement. MRI typically shows a well-circumscribed, dural-based mass with avid homogeneous enhancement and can delineate optic nerve involvement, carotid proximity, and severity of chiasmal distortion to support approach selection. Compar
Intracranial aneurysms and vascular compression of the chiasm are important causes of optic neuropathy and chiasmal compression, most often arising from the internal carotid artery but also from adjacent vessels capable of abutting the anterior visual pathway. Patients typically present with progressive visual field defects; prechiasmatic optic nerve compression may cause unilateral optic neuropathy, sometimes with pain, depending on location and mass effect[40]. Neuro-ophthalmic cohorts have reported that supraclinoid internal carotid artery aneurysms can mimic tumor-like compressive optic neuropathy if vascular imaging is not pursued. High-resolution MRI can demonstrate direct neurovascular contact, while MRA defines aneurysm morphology and mass effect on the optic chiasm[41].
Imaging-based anatomy is crucial because several management strategies exist and visual outcomes vary by treatment. Aneurysm size, neck configuration, dome direction, and relationship to the optic chiasm and carotid branches guide treatment selection (microsurgical clipping, coiling, or flow diversion)[40]. When MRA shows compressive anatomy, early treatment is associated with a higher likelihood of symptomatic improvement in unruptured internal carotid artery aneurysms treated with flow diversion[42].
Ischemic injury to the anterior visual pathways can produce acute vision loss that poses diagnostic challenges in neuro-ophthalmology. Vascular pathologies affecting the optic nerve and chiasm include ischemic optic neuropathies and rare neurovascular compressive syndromes. MRI is pivotal in differentiating these entities from mimickers like demyelination or compressive tumors. Key imaging techniques – including DWI, contrast-enhanced MRI, and MRA – help characterize ischemic lesions and reveal causative vascular abnormalities. Below, we review ischemic optic neuropathies (arteritic vs nonarteritic), chiasmal ischemia (stroke-related and aneurysmal), uncommon vascular compressions, the utility of MRA/perfusion, and correlations with systemic vascular risk factors. Pragmatic MRI features that help differentiate ischemic optic neuropathy from inflammatory optic neuritis are summarized in Figure 5.
Anterior ischemic optic neuropathy (AION) may be nonarteritic-AION (NA-AION), typically due to small-vessel disease, or arteritic-AION (A-AION), most often caused by giant cell arteritis. Differentiating these is critical, as A-AION requires emergent treatment to prevent bilateral blindness. Clinically, both present with sudden painless monocular vision loss and optic disc edema, but MRI can provide distinguishing clues. On DWI, acute A-AION more often shows restricted diffusion in the optic nerve (with corresponding low ADC values) compared with NA-AION[43]. In one recent cohort study, optic nerve diffusion restriction was seen in approximately 83% of A-AION vs approximately 42% of NA-AION cases, reflecting more extensive infarction in arteritic cases. Contrast-enhanced MRI further differentiates these subtypes. Arteritic AION often demonstrates an optic nerve head enhancement known as the “central bright spot” on fat-saturated postcontrast T1 images. This central enhancement represents ischemia of the optic disc and is highly suggestive of giant cell arteritis in the appropriate context[44]. By contrast, NA-AION usually shows minimal or no optic nerve enhan
Posterior ischemic optic neuropathy (PION) is a less common variant where the ischemic insult occurs in the re
Ischemic injury to the optic chiasm is rare due to the rich collateral blood supply from the circle of Willis. However, strokes involving small perforating arteries can infarct the chiasm, typically presenting as bitemporal hemianopsia or, in extreme cases, bilateral blindness. Acute optic chiasm infarction is most often seen in the setting of global hypoperfusion or complex vascular procedures. Diffusion-weighted MRI is diagnostic in such cases: Diffusion restriction confined to the chiasm (and sometimes extending to optic tracts) appears as high DWI signal with low ADC, confirming an acute infarct. For instance, a recent case report documented sudden bilateral vision loss with MRI showing FLAIR hyperintensity and DWI restriction in the optic chiasm, consistent with an infarction in that location[47]. This “chiasmal stroke” occurred after mechanical thrombectomy for an internal carotid occlusion, illustrating that iatrogenic or hemodynamic insults can selectively injure the chiasm[48]. Although uncommon, recognizing a chiasmal diffusion lesion is crucial: It localizes the lesion and prompts evaluation for stroke mechanisms (often warranting vascular imaging to assess the circle of Willis and cardiac sources).
Anterior cerebral artery aneurysms – particularly those of the anterior communicating artery (ACom) complex – can also affect the chiasm and optic nerves. An unruptured ACom aneurysm typically causes gradual visual decline by compressing the optic chiasm or one optic nerve (classically a junctional scotoma with ipsilateral optic nerve loss and contralateral temporal field deficit). These compressive effects are considered under “rare vascular compression” below. Importantly, an anterior cerebral artery region aneurysm may present acutely if it ruptures or causes arterial compromise. A ruptured ACom aneurysm can lead to ischemic chiasmopathy via subarachnoid hemorrhage and vasospasm or direct hematoma impinging on the chiasm[49]. In a surgical series of ruptured ACom aneurysms, 10 out of 33 patients had preoperative visual symptoms from either direct optic apparatus compression or focal hematoma around the optic nerve/chiasm, some with unilateral blindness or field defects that improved after clipping. Thus, both compression and ischemia contribute: The aneurysm’s proximity to the chiasm means that even a small aneurysm, if directed upward, can compromise the crossing fibers or blood supply[49]. From a radiologic standpoint, any patient with unexplained chiasmal syndrome should undergo vascular imaging to exclude an aneurysm in the suprasellar region. Notably, even a small aneurysm can mimic other pathologies; Bhat and Sampath[50] reported an ACom aneurysm that presented as acute unilateral optic neuropathy (monocular blindness), initially resembling optic neuritis. In such cases, MRI may show subtle optic nerve signal change but MRA reveals the aneurysm, underscoring the need for a high index of suspicion. Overall, stroke-related chiasmal ischemia and aneurysm-related visual loss are rare, but radiologists must include vascular etiologies in the differential diagnosis of chiasmal lesions, especially in older patients or those with vascular risk factors.
Aside from aneurysms, truly rare cases exist where an elongated or ectatic artery compresses the optic nerve or chiasm without overt hemorrhage. Neurovascular compression syndromes are well known for cranial nerves V and VII, but involvement of the optic pathways is exceptional. Reported instances include dolichoectatic basilar arteries compressing an optic tract and causing homonymous hemianopia, as well as highly tortuous internal carotid arteries impinging on an optic nerve with resultant peripheral field loss[51]. Such compression is usually a chronic process, producing slowly progressive vision loss that can be mistaken for glaucomatous or compressive optic neuropathy. MRI may demonstrate the offending vessel as a flow void in close contact with the optic nerve/chiasm, sometimes “sandwiching” the nerve between an artery and the skull base. MRA or CT angiography can delineate the vessel’s anatomy in relation to the optic apparatus. Because these cases are so uncommon, management is individualized – surgical vascular decompression carries significant risk (including stroke), so conservative management is often favored unless vision loss is severe or progressive[51]. From a diagnostic perspective, recognizing a neurovascular contact as the cause of an optic neuropathy is important to avoid unnecessary biopsies or immunotherapy. The radiologist should carefully inspect high-resolution T2 or constructive interference (CISS/FIESTA) sequences in patients with unexplained optic nerve atrophy, especially if typical causes (tumor, demyelination, ischemia) are absent. Detection of a compressive artery can explain the clinical picture and guide neurosurgical consultation. Though rare, these vascular compressions highlight the breadth of pathology that MRI can unveil in the anterior visual pathway.
MRA: Incorporating MRA in the MRI protocol is highly valuable when ischemic optic neuropathy or chiasmal syndrome is suspected. MRA can noninvasively reveal intracranial aneurysms, arterial stenoses, or occlusions that directly impact the optic pathways. For example, in a patient over 50 with acute optic neuropathy and no obvious demyelinating lesion, an MRA can be critical to detect an ACom aneurysm or carotid occlusion that would alter management. In fact, experts have emphasized that an unexplained visual loss (with normal brain CT) warrants cerebral vascular imaging to rule out an aneurysm before it ruptures[49]. In giant cell arteritis, dedicated magnetic resonance or CT angiography of the head and neck may show luminal narrowing in the extracranial carotid or ophthalmic arteries, but conventional MRA is often normal since the ischemia is in the microcirculation (short posterior ciliary arteries). Advanced MRI techniques like black-blood vessel wall imaging can directly demonstrate inflamed arterial walls in giant cell arteritis, although this is a specialized application. More routinely, orbital MRA helps by assessing the patency of the ophthalmic arteries and cavernous carotids in suspected ocular ischemic syndrome. If a patient has signs of ocular ischemic syndrome (e.g., mid-peripheral retinal hemorrhages, carotid bruit), an MRA or carotid ultrasound is indicated to identify high-grade carotid stenosis. Detecting a treatable vascular lesion (such as an aneurysm or carotid plaque) is arguably the most important contribution of imaging in ischemic optic neuropathies beyond confirming the diagnosis.
Perfusion MRI: While not yet part of standard practice for optic nerve evaluation, perfusion imaging techniques are emerging as informative adjuncts. Arterial spin labeling (ASL) perfusion MRI can quantify blood flow in the optic nerve, chiasm, and retina without contrast. Recent research demonstrates that ASL can differentiate ocular ischemic syndrome due to carotid occlusive disease from other causes of vision loss. In one study, patients with ocular ischemic syndrome showed significantly reduced perfusion in the intraorbital optic nerves and retina-choroid complex compared to controls[52]. The optic nerve blood flow in severe carotid stenosis was so diminished that ASL-based measurements at certain post-labeling delays had a high accuracy (area under the curve > 0.8) for identifying ocular ischemia[52]. This suggests a future role for noninvasive perfusion MRI in diagnosing chronic ischemia before structural damage is irreversible. Additionally, contrast perfusion (dynamic susceptibility) MRI is occasionally used in research to detect “luxury perfusion” or hyperemia in optic nerves after infarction, though its clinical utility is limited[52]. Overall, perfusion imaging can provide functional insight – for example, confirming globally reduced optic nerve perfusion in hypotensive ischemic optic neuropathy or monitoring revascularization effects. Combining perfusion data with structural MRI might improve early diagnosis of ischemia when conventional MRI findings are equivocal. As these techniques advance, radiologists and ophthalmologists could employ them to gauge ischemia severity and perhaps to monitor response to treatments like carotid endarterectomy or vasculitis therapy.
Ischemic optic neuropathies lie at the crossroads of ophthalmology and systemic vascular disease. Nonarteritic AION is strongly associated with cardiovascular risk factors – a meta-analysis confirmed hypertension, hyperlipidemia, diabetes, ischemic heart disease, and obstructive sleep apnea as significant risk factors for NA-AION[53]. These patients often have a “disc-at-risk” anatomy (small crowded optic disc) and suffer nocturnal hypotension or other perfusion drops that precipitate the optic nerve head infarct. The systemic profile of NA-AION overlaps with that of stroke, so a diagnosis of NA-AION should prompt optimization of vascular risk factors (blood pressure, glycemic control, lipid levels) and screening for sleep apnea. Though no proven therapy can reverse NA-AION, aggressive vascular risk reduction is thought to help prevent fellow-eye involvement or future cerebrovascular events. In contrast, arteritic AION (giant cell arteritis) is an inflammatory vasculitis of medium/Large arteries, but it too has systemic implications. It typically affects patients over 70 and is often accompanied by systemic symptoms (headache, jaw claudication, polymyalgia rheumatica). Radiologists who identify imaging signs of arteritic AION (e.g., optic nerve enhancement or bilateral posterior ciliary artery occlusions on angiography) should immediately alert the clinical team, as prompt high-dose corticosteroids can be vision-saving. The correlation with systemic markers (e.g., elevated ESR/CRP) is crucial; imaging supports the diagnosis but does not replace temporal artery biopsy in giant cell arteritis.
Chiasmal ischemia or optic tract infarctions usually indicate significant cerebrovascular disease. A chiasm stroke should spur evaluation for underlying causes such as internal carotid artery stenosis, embolic sources, or severe hypotensive episodes – essentially treating it as one would a small deep brain infarct. Likewise, an ocular ischemic syndrome diagnosis is a red flag for carotid occlusive disease requiring possible surgical intervention. Even the rare vascular compressions of the optic nerve often relate to widespread atherosclerosis and vessel tortuosity (as seen in older patients with hypertension or hyperlipidemia)[51]. In these cases, the radiologist’s detection of the vascular cause can direct management toward vascular risk modification when neurosurgical decompression is not feasible. In summary, radiologic recognition of ischemic optic neuropathies and their vascular etiologies has direct ophthalmic and systemic relevance. It facilitates interdisciplinary care: (1) The ophthalmologist addresses the visual rehabilitation; (2) The rheumatologist or neurologist manages arteritic inflammation; and (3) The internist or cardiologist optimizes systemic vascular health. By correlating MRI findings with systemic risk factors, clinicians can not only treat the eye condition but also mitigate broader health risks (such as stroke, myocardial infarction, or aneurysm rupture). This underscores the importance of a comprehensive approach – the eye may be the first site of “end-organ” damage from vascular disease, serving as a warning sign to evaluate and treat the patient as a whole.
Ultra-high-field MRI is poised to expand the ceiling of what we can resolve in the anterior visual pathway. As 7T platforms become more available and protocols mature, the improved signal-to-noise ratio can translate into finer depiction of the optic nerve sheath complex, intraneural microstructure, small perineural vessels, and subtle chiasmal distortion. In parallel, ongoing refinement in fat suppression, motion correction, and susceptibility management may improve reliability in the orbit – where artifacts remain a practical barrier – while enabling thinner slices and more confident assessment of small lesions at the orbital apex and optic canal[10].
Artificial intelligence and radiomics represent a second major frontier. For optic nerve and chiasmal disease, artificial intelligence can help with automated segmentation of the optic nerve, chiasm, and tracts; standardized quantification of T2 hyperintensity and enhancement burden; and extraction of “invisible” textural features that may correlate with inflammatory activity, tumor cellularity, or microvascular injury. The near-term clinical value is likely to be decision support: Flagging subtle abnormalities on busy studies, harmonizing follow-up comparisons across scanners, and producing objective metrics that can be trended over time. The most meaningful systems will be those trained on multi-center data and evaluated against clinically relevant endpoints, such as visual recovery, relapse risk, or treatment response[54].
A particularly promising direction is integrating OCT biomarkers with MRI. OCT provides high-resolution structural readouts of the retina and retinal nerve fiber layer, while MRI contextualizes disease location, extent, and etiology along the entire anterior visual pathway. Multimodal models that align OCT-derived axonal loss with MRI-defined lesion topography could sharpen clinico-radiologic correlation, distinguish irreversible injury from active inflammation, and refine follow-up strategies. Practically, this could support earlier recognition of atypical optic neuritis phenotypes, better risk stratification after a first demyelinating event, and more consistent monitoring of compressive lesions where structure-function dissociation is common.
Finally, the field is moving toward prognostication and personalized medicine. Rather than treating MRI as a binary “positive/negative” test, emerging approaches emphasize patterns that predict outcome: (1) Lesion length and location; (2) Degree and configuration of enhancement; (3) Diffusion abnormalities; (4) Tract/chiasmal involvement; and (5) Quantitative microstructural metrics. As these imaging features are paired with serologic markers, clinical phenotypes, and longitudinal visual function data, clinicians may be able to tailor urgency, testing, and therapy intensity to an individual patient’s predicted trajectory.
Artifacts: MRI, despite its powerful diagnostic capabilities, is subject to various artifacts that can limit image quality and interpretation. Artifacts arise from various sources such as patient movement, hardware defects, and the physical principles of the MRI itself. Common artifacts include motion artifacts, caused by voluntary or involuntary patient movement (respiration or vessel pulsation), which often result in image blurring or ghosting. Susceptibility artifacts happen in the vicinity of tissue interfaces or metallic implants because of local magnetic field distortions, resulting in signal loss. Another frequent artifact is chemical shift artifact, resulting from differences in resonance frequencies between fat and water protons, which can cause misregistration at fat water boundaries. Additionally, partial volume artifacts arise when a single voxel contains different tissue types, causing averaging of signals and loss of fine detail[5].
Despite offering superior soft tissue contrast and valuable diagnostic detail, MRI is limited by significant challenges related to cost and accessibility. The high financial burden associated with MRI starts with the initial cost of acquiring and implementing these systems, which can reach approximately $1 million per tesla of magnetic field strength. In addition to equipment expenses, specialized infrastructure, trained personnel, and constant technical support contribute to the overall high cost. These financial demands make MRI less accessible in low resource regions and can lead to disparities in availability. These costs represent a barrier to access for patients without healthcare support. As a result, although MRI is a powerful imaging modality, its clinical utility may be restricted by economic and logistical barriers in many healthcare settings[11].
MRI has become central to evaluating optic nerve and chiasmal disease because it localizes pathology, characterizes tissue behavior, and guides time-sensitive management when the clinical phenotype overlaps. A pattern-based approach helps clinicians move from “optic neuropathy” to a narrower etiologic differential: (1) Short-segment enhancement without chiasmal extension supports typical demyelinating optic neuritis; (2) Longitudinally extensive involvement or chiasmal extension increases suspicion for antibody-mediated disease and prompts targeted serology and broader neuraxis imaging; (3) Sheath-based enhancement and orbital inflammatory patterns should raise concern for granulomatous or infiltrative etiologies; and (4) Discrete anatomic compression from sellar/parasellar masses or aneurysms reframes the problem as one of structural compromise requiring timely surgical or endovascular planning.
For clinicians, the practical message is straightforward. MRI should be ordered urgently when visual loss is severe, progressive, atypical, bilateral, associated with pain out of proportion, accompanied by neurological signs, or when examination and OCT do not explain the deficit. Dedicated orbital sequences with fat suppression and contrast, coupled with brain imaging when indicated, are essential to avoid false reassurance. When vascular pathology is suspected – older age, systemic symptoms, or profound acute deficits – diffusion imaging and vascular evaluation can provide supportive evidence, but clinical judgment remains paramount and treatment should not be delayed when arteritic disease is likely.
Beyond establishing a diagnosis, MRI plays a central role in guiding systemic evaluation, risk stratification, and multidisciplinary management. It informs systemic workup, stratifies risk, determines urgency, and helps coordinate care across ophthalmology, neurology, radiology, neurosurgery, rheumatology, and oncology. By recognizing high-yield patterns and integrating them with clinical data, clinicians can deliver faster, more accurate, and more patient-centered management of optic nerve and chiasmal disorders.
| 1. | Hoch MJ, Bruno MT, Shepherd TM. Advanced MRI of the Optic Nerve. J Neuroophthalmol. 2017;37:187-196. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 21] [Cited by in RCA: 33] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
| 2. | Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727-732. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 151] [Cited by in RCA: 204] [Article Influence: 11.3] [Reference Citation Analysis (0)] |
| 3. | Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-189. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4049] [Cited by in RCA: 3562] [Article Influence: 323.8] [Reference Citation Analysis (1)] |
| 4. | Biousse V, Newman NJ. Ischemic Optic Neuropathies. N Engl J Med. 2015;372:2428-2436. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 163] [Cited by in RCA: 242] [Article Influence: 22.0] [Reference Citation Analysis (0)] |
| 5. | Grover VP, Tognarelli JM, Crossey MM, Cox IJ, Taylor-Robinson SD, McPhail MJ. Magnetic Resonance Imaging: Principles and Techniques: Lessons for Clinicians. J Clin Exp Hepatol. 2015;5:246-255. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 393] [Cited by in RCA: 231] [Article Influence: 21.0] [Reference Citation Analysis (1)] |
| 7. | Niknejad MT, Wilczek M, Sriselvakumar S. Fat suppressed imaging. Radiopaedia.org 2013. [DOI] [Full Text] |
| 8. | Widmann G, Henninger B, Kremser C, Jaschke W. MRI Sequences in Head & Neck Radiology - State of the Art. Rofo. 2017;189:413-422. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 33] [Cited by in RCA: 62] [Article Influence: 6.9] [Reference Citation Analysis (0)] |
| 9. | Chow LS, Paley MNJ. Recent advances on optic nerve magnetic resonance imaging and post-processing. Magn Reson Imaging. 2021;79:76-84. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 9] [Cited by in RCA: 19] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
| 10. | Glarin RK, Nguyen BN, Cleary JO, Kolbe SC, Ordidge RJ, Bui BV, McKendrick AM, Moffat BA. MR-EYE: High-Resolution MRI of the Human Eye and Orbit at Ultrahigh Field (7T). Magn Reson Imaging Clin N Am. 2021;29:103-116. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4] [Cited by in RCA: 17] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
| 11. | Pomara C, Pascale N, Maglietta F, Neri M, Riezzo I, Turillazzi E. Use of contrast media in diagnostic imaging: medico-legal considerations. Radiol Med. 2015;120:802-809. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 18] [Cited by in RCA: 33] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
| 13. | Gaillard F, Sharma R, Campos A. Neuromyelitis optica spectrum disorder. Radiopaedia.org 2008. [DOI] [Full Text] |
| 14. | Gaillard F, Sharma R, Agazzi GM. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Radiopaedia.org 2018. [DOI] [Full Text] |
| 16. | Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182:289-295. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 194] [Cited by in RCA: 171] [Article Influence: 7.8] [Reference Citation Analysis (0)] |
| 17. | Pawate S. Sarcoidosis and the Nervous System. Continuum (Minneap Minn). 2020;26:695-715. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 18. | de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol. 2017;37 Suppl 1:S23-S32. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 66] [Cited by in RCA: 98] [Article Influence: 10.9] [Reference Citation Analysis (0)] |
| 19. | Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, Salvador H, Azizi AA, Mautner V, Röhl C, Peltonen S, Stivaros S, Legius E, Oostenbrink R; ERN GENTURIS NF1 Tumour Management Guideline Group. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 92] [Article Influence: 30.7] [Reference Citation Analysis (0)] |
| 20. | Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR; Council on Genetics; American College of Medical Genetics and Genomics. Health Supervision for Children with Neurofibromatosis Type 1. Pediatrics. 2019;143:e20190660. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 150] [Cited by in RCA: 143] [Article Influence: 20.4] [Reference Citation Analysis (0)] |
| 21. | Zeid JL. Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1. Front Surg. 2022;9:908573. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 11] [Reference Citation Analysis (0)] |
| 22. | Wang MX, Dillman JR, Guccione J, Habiba A, Maher M, Kamel S, Panse PM, Jensen CT, Elsayes KM. Neurofibromatosis from Head to Toe: What the Radiologist Needs to Know. Radiographics. 2022;42:1123-1144. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 31] [Article Influence: 7.8] [Reference Citation Analysis (0)] |
| 23. | Horowitz T, Salgues B, Padovani L, Farah K, Dufour H, Chinot O, Guedj E, Graillon T. Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with (68)Ga-DOTATOC PET/CT. Diagnostics (Basel). 2023;13:2307. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 24. | Vanikieti K, Chaiwithooanukul C, Puataweepong P, Jindahra P, Padungkiatsagul T. Long-Term Visual Function After Fractionated Stereotactic Radiotherapy for Primary Optic Nerve Sheath Meningioma: A Retrospective Analysis of 34 Subjects. Clin Ophthalmol. 2022;16:3119-3128. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 25. | de Melo LP, Arruda Viani G, de Paula JS. Radiotherapy for the treatment of optic nerve sheath meningioma: A systematic review and meta-analysis. Radiother Oncol. 2021;165:135-141. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 16] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
| 26. | Deng MY, Rauh S, Anil G, Lischalk JW, Hahnemann L, Eichkorn T, Hörner-Rieber J, Paul A, Sandrini E, Hoegen-Sassmannshausen P, Held T, Regnery S, Bauer L, Sahm F, von Deimling A, Wick A, Wick W, Jungk C, Krieg SM, Herfarth K, Debus J, König L. Analysis of safety and efficacy of proton radiotherapy for optic nerve sheath meningioma. Neurooncol Adv. 2024;6:vdae160. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 27. | Goyal P, Lee S, Gupta N, Kumar Y, Mangla M, Hooda K, Li S, Mangla R. Orbital apex disorders: Imaging findings and management. Neuroradiol J. 2018;31:104-125. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 23] [Cited by in RCA: 34] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
| 28. | Khan SN, Sepahdari AR. Orbital masses: CT and MRI of common vascular lesions, benign tumors, and malignancies. Saudi J Ophthalmol. 2012;26:373-383. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 65] [Cited by in RCA: 76] [Article Influence: 5.8] [Reference Citation Analysis (0)] |
| 29. | Ribas GA, de Mori LH, Freddi TAL, Oliveira LDS, de Souza SR, Corrêa DG. Primary central nervous system lymphoma: Imaging features and differential diagnosis. Neuroradiol J. 2024;37:705-722. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 8] [Cited by in RCA: 15] [Article Influence: 7.5] [Reference Citation Analysis (0)] |
| 30. | Tejani AS, Berson E, Phillip J, Feltrin FS, Bazan C, Raj KM, Agarwal AK, Maldjian JA, Lee WC, Yu FF. Diffusion-weighted imaging of the orbit. Clin Radiol. 2024;79:10-18. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 31. | Gupta L, Peterson EL, Williams C, Altman E, Harpole R, Martin DJ, Escott EJ, Timoney PJ, Prendes MA. Diffusion-Weighted Imaging of the Orbit: A Case Series and Systematic Review. Ophthalmic Plast Reconstr Surg. 2023;39:407-418. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 32. | Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees. Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;S0923-7534(23)05074. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 41] [Reference Citation Analysis (0)] |
| 33. | Shih RY, Schroeder JW, Koeller KK. Primary Tumors of the Pituitary Gland: Radiologic-Pathologic Correlation. Radiographics. 2021;41:2029-2046. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 28] [Cited by in RCA: 21] [Article Influence: 4.2] [Reference Citation Analysis (1)] |
| 34. | Lee IH, Miller NR, Zan E, Tavares F, Blitz AM, Sung H, Yousem DM, Boland MV. Visual Defects in Patients With Pituitary Adenomas: The Myth of Bitemporal Hemianopsia. AJR Am J Roentgenol. 2015;205:W512-W518. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 42] [Cited by in RCA: 58] [Article Influence: 5.8] [Reference Citation Analysis (0)] |
| 35. | Tsukamoto T, Miki Y. Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma. Jpn J Radiol. 2023;41:789-806. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 50] [Article Influence: 16.7] [Reference Citation Analysis (0)] |
| 36. | Lucia K, Gudehus A, Seifert V, Czabanka M, Jussen D. The Role of Tumor-Associated Hypothalamic Involvement in Surgical Treatment and Long-Term Outcome in Adult Patients with Craniopharyngioma. World Neurosurg. 2024;182:e525-e535. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 37. | Na MK, Jang B, Choi KS, Lim TH, Kim W, Cho Y, Shin HG, Ahn C, Kim JG, Lee J, Kwon SM, Lee H. Craniopharyngioma resection by endoscopic endonasal approach versus transcranial approach: A systematic review and meta-analysis of comparative studies. Front Oncol. 2022;12:1058329. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5] [Cited by in RCA: 26] [Article Influence: 6.5] [Reference Citation Analysis (0)] |
| 38. | Yi C, Li L, Ma J. Tumor enhancement and shrinkage pattern in dynamic contrast-enhanced magnetic resonance imaging for predicting pathologic complete response after human epidermal growth factor receptor 2 (HER2)-targeted therapy in breast cancer. Quant Imaging Med Surg. 2024;14:6734-6744. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 39. | Marian-Magaña R, Sangrador-Deitos MV, Rodríguez-Hernández L, Lara-Olivas JA, López-Valencia G, Villalobos-Díaz R, Aragón-Arreola JF, Padilla-Leal KE, García-Zazueta JH, Camacho-Castro A, Gómez-Amador JL. Visual outcomes in tuberculum sellae meningiomas comparing transcranial and endoscopic endonasal approaches. World Neurosurg X. 2024;23:100319. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 40. | Silva MA, See AP, Dasenbrock HH, Patel NJ, Aziz-Sultan MA. Vision outcomes in patients with paraclinoid aneurysms treated with clipping, coiling, or flow diversion: a systematic review and meta-analysis. Neurosurg Focus. 2017;42:E15. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 39] [Cited by in RCA: 58] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
| 41. | Tsutsumi S, Ono H, Yasumoto Y. Vascular Compression of the Anterior Optic Pathway: A Rare Occurrence? Can Assoc Radiol J. 2017;68:409-413. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 9] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
| 42. | Kaiser DPO, Cuberi A, Linn J, Gawlitza M. Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro-ophthalmological symptoms: a systematic review and meta-analysis. J Neurointerv Surg. 2023;15:892-897. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 8] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
| 43. | Pietrock C, Knoche T, Meidinger S, Wenzel V, Neumann K, Siebert E, Danyel LA. Diffusion weighted imaging-based differentiation of arteritic and non-arteritic anterior ischemic optic neuropathy. BMC Med Imaging. 2025;25:208. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 44. | Remond P, Attyé A, Lecler A, Lamalle L, Boudiaf N, Aptel F, Krainik A, Chiquet C. The Central Bright Spot Sign: A Potential New MR Imaging Sign for the Early Diagnosis of Anterior Ischemic Optic Neuropathy due to Giant Cell Arteritis. AJNR Am J Neuroradiol. 2017;38:1411-1415. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 15] [Cited by in RCA: 31] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
| 45. | Li W, Bhattacharya SK. Narrative review: advances in ischemic optic neuropathy: classification, diagnosis tools, experimental models, and treatments. Ann Eye Sci. 2025;10:22-22. [DOI] [Full Text] |
| 46. | Fideles R, Coelho M, Araújo J, Gonçalves C, Henriques C, Costa A. A Case of Optic Chiasm Stroke, A Condition Rarely Described in the Literature. Eur J Case Rep Intern Med. 2024;11:004213. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 47. | Al-Zubidi N, Stevens S, Fung SH, Lee AG. Diffusion-weighted imaging in posterior ischemic optic neuropathy. Can J Ophthalmol. 2014;49:e21-e25. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 11] [Cited by in RCA: 13] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
| 48. | Sigireddi RR, Bhat N, Raviskanthan S, Mortensen PW, Harish Bindiganavile S, Klucznik R, Lee AG. Bitemporal hemianopsia secondary to ischemic chiasmopathy following mechanical thrombectomy. Am J Ophthalmol Case Rep. 2021;23:101191. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 49. | Park JH, Park SK, Kim TH, Shin JJ, Shin HS, Hwang YS. Anterior communicating artery aneurysm related to visual symptoms. J Korean Neurosurg Soc. 2009;46:232-238. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 23] [Cited by in RCA: 36] [Article Influence: 2.1] [Reference Citation Analysis (0)] |
| 50. | Bhat DI, Sampath S. Anterior communicating artery aneurysm presenting as monocular blindness. Br J Neurosurg. 2011;25:644-646. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 7] [Cited by in RCA: 10] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
| 51. | von Wild K, Busse H. [Neurovascular compression of the optic nerve as a cause of progressive visual dysfunctions and decompression treatment]. Klin Monbl Augenheilkd. 1990;196:460-465. [PubMed] |
| 52. | Chen Y, Feng X, Huang Y, Zhao L, Chen X, Qin S, Sun J, Jing J, Zhang X, Wang Y. Blood flow perfusion in visual pathway detected by arterial spin labeling magnetic resonance imaging for differential diagnosis of ocular ischemic syndrome. Front Neurosci. 2023;17:1121490. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 53. | Liu B, Yu Y, Liu W, Deng T, Xiang D. Risk Factors for Non-arteritic Anterior Ischemic Optic Neuropathy: A Large Scale Meta-Analysis. Front Med (Lausanne). 2021;8:618353. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 4] [Cited by in RCA: 53] [Article Influence: 10.6] [Reference Citation Analysis (0)] |
| 54. | Waisberg E, Ong J, Kamran SA, Masalkhi M, Paladugu P, Zaman N, Lee AG, Tavakkoli A. Generative artificial intelligence in ophthalmology. Surv Ophthalmol. 2025;70:1-11. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 26] [Article Influence: 26.0] [Reference Citation Analysis (0)] |